Stemline Therapeutics (NASDAQ:STML) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

Several other research firms have also recently weighed in on STML. HC Wainwright reissued a “buy” rating and set a $38.00 price target on shares of Stemline Therapeutics in a report on Friday, November 10th. Cowen reissued a “buy” rating on shares of Stemline Therapeutics in a report on Tuesday, October 31st. Finally, ValuEngine cut Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $33.40.

Stemline Therapeutics (NASDAQ:STML) traded up $0.45 during mid-day trading on Thursday, reaching $14.97. The company had a trading volume of 214,681 shares, compared to its average volume of 274,766. Stemline Therapeutics has a fifty-two week low of $5.50 and a fifty-two week high of $15.95.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Voya Investment Management LLC bought a new position in shares of Stemline Therapeutics during the 2nd quarter valued at $102,000. Nationwide Fund Advisors increased its stake in shares of Stemline Therapeutics by 7.2% in the 2nd quarter. Nationwide Fund Advisors now owns 12,755 shares of the biopharmaceutical company’s stock worth $117,000 after purchasing an additional 855 shares in the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Stemline Therapeutics in the 2nd quarter worth $147,000. Alliancebernstein L.P. purchased a new stake in shares of Stemline Therapeutics in the 2nd quarter worth $178,000. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Stemline Therapeutics by 40.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,279 shares of the biopharmaceutical company’s stock worth $178,000 after purchasing an additional 5,522 shares in the last quarter. 50.24% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Stemline Therapeutics (STML) Downgraded by BidaskClub” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/07/stemline-therapeutics-stml-downgraded-by-bidaskclub.html.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.